NCT05464667 |
Preoperative Irradiation for Stage I Breast Cancer |
NCT05528133 |
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer |
NCT03043794 |
Study of Stereotactic Radiotherapy for Breast Cancer |
NCT02958774 |
Hypofractionated Radiation Therapy for Patients With Breast Cancer Receiving Regional Nodal Irradiation |
NCT04990921 |
Study of Palliative Radiation Combined With Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer |
NCT04360330 |
SABER Study for Selected Early Stage Breast Cancer |
NCT05472792 |
Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN) |
NCT04454528 |
BreastVAX: Radiation Boost to Enhance Immune Checkpoint Blockade Therapy |
NCT05856773 |
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy |
NCT06139107 |
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole |
NCT06129747 |
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast |
NCT05591547 |
Evaluating the Safety and Efficacy of a Novel Accelerated Partial Breast Irradiation Regimen for patIents With Favorable Risk breaSt cancEr |
NCT06008158 |
Evaluation of a Once Per Day Regimen of Accelerated Partial Breast Irradiation for Improved Breast Appearance in Patients With Low Risk, Hormone Responsive Breast Cancer |
NCT04648904 |
Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer |
NCT05996107 |
Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, Node Positive, HR+/HER2- Breast Cancer |
NCT04040569 |
A Phase I Dose Escalation Study of Single Fraction Ablative Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer |
NCT03945721 |
A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer Patients |
NCT04849871 |
Single Fraction Accelerated Partial Breast Irradiation vs. Five Fraction Accelerated Partial Breast Irradiation for Low-risk Stage 0 and I Breast Carcinoma |
NCT04923542 |
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases |
NCT05491226 |
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation |
NCT04965688 |
Systems Biology Guided Therapy for Breast Cancer Positive for Oestrogen Receptor After Aromatase Inhibitor and CDK Inhibition |
NCT02977468 |
Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer |
NCT04443413 |
Phase III Study of 5tx vs 15tx of RT (X-rays or Protons) Including RNI in Breast Cancer Patients |
NCT04234386 |
GammaPod Dose Escalation Radiation for Early Stage Breast Cancer |
NCT04837209 |
Radiation, Immunotherapy and PARP Inhibitor in Triple Negative Breast Cancer |
NCT05774678 |
Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Nanomechanical Biomarker Evaluation |
NCT05731791 |
Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation |
NCT03909282 |
Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma |
NCT05288777 |
Adjuvant Chemoradiation and Biomarkers of Response in High-risk Breast Cancer |
NCT05766891 |
Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery |
NCT03789097 |
Vaccination With Flt3L, Radiation, and Poly-ICLC |
NCT06295744 |
Outcomes and Cosmesis With Whole Breast Irradiation and Boost |
NCT05456373 |
Intraoperative Use of ClearEdge Device in Breast Conserving Surgery |
NCT05289466 |
Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation. |
NCT05245812 |
Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy |
NCT05912231 |
Ultrahypofractionation and Normal Tissue Toxicity |
NCT04959474 |
SABR-CaRe in Early Stage Breast Cancer |
NCT05340673 |
Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer |
NCT05607017 |
Losartan in Prevention of Radiation-Induced Heart Failure |
NCT05269160 |
Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ) |
NCT06185205 |
ASHBY: Accelerated Super-Hypofractionated Breast Brachytherapy |
NCT04175210 |
Prospective Randomized Study of Accelerated Radiation Therapy (PRART) |
NCT04563507 |
Combined Immunotherapies in Metastatic ER+ Breast Cancer |
NCT03979508 |
Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer |
NCT05130801 |
A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery |
NCT02926729 |
Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy |
NCT03216421 |
Intraoperative Radiation Therapy (IORT) in DCIS |
NCT02807597 |
Real-time Intraoperative Breast Cancer Visualization for Margin Assessment |
NCT05710328 |
Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial |
NCT06006806 |
Evaluation of Radiobiological Effects in Skin Toxicities for Breast Cancer Patients With Pencil Beam Scanning Proton Therapy |
NCT05637216 |
Losartan to Reduce Radiation Induced Fibrosis in Breast Cancer Patients |
NCT05755984 |
3D Printed Breast Models in the Surgical Management of Breast Cancer |
NCT04233385 |
Myofascial Massage for Pain and Immobility Following Breast Cancer Surgery |
NCT03796273 |
Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases |
NCT01185132 |
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy |
NCT04225585 |
Well-Being After Breast Cancer Surgery |
NCT02927912 |
Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction |
NCT06127979 |
A Study of Changes in Ki67 Expression in People With Breast Cancer Receiving Endocrine Therapy Before Surgery |
NCT05892068 |
A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain |
NCT05374915 |
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC) |
NCT04371913 |
Personalized Second Chance Breast Conservation (PSCBC): A Prospective Phase II Clinical Study |
NCT04674306 |
Adjuvant Therapy With an Alpha-lactalbumin Vaccine in Triple-Negative Breast Cancer |
NCT04815083 |
Fluorescence Imaging of Carcinoma During Breast Conserving Surgery |
NCT05351424 |
AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc |
NCT03488693 |
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer |
NCT05705401 |
Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer |
NCT05504707 |
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer |
NCT06275126 |
Optimizing Surgical Decisions in Young Adults With Breast Cancer |
NCT04993313 |
Standard Verbal Counseling With or Without a Pictorial Educational Tool for the Reduction of Psychological Morbidity in Patients With Stage 0-IIIA Breast Cancer Receiving Radiation Therapy, COPE Study |
NCT03765983 |
GDC-0084 in Combination With Trastuzumab for Patients With HER2-Positive Breast Cancer Brain Metastases |
NCT04588545 |
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease |
NCT01766297 |
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer |
NCT04852887 |
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) |
NCT06229392 |
A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer |
NCT04270149 |
Cancer Peptides Plus GM-CSF and Adjuvant in Breast Cancer |
NCT04020575 |
Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) |
NCT05325632 |
Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab |
NCT01570998 |
Intraoperative Radiation Therapy in Treating Patients With Breast Cancer Undergoing Breast-Conserving Surgery |
NCT04427293 |
Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC) |
NCT05412225 |
A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer |
NCT04329065 |
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer |
NCT05378464 |
Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer |
NCT05447910 |
Analysis of Letrozole in Patients With Operable Hormone Receptor Positive, HER2 Negative Breast Cancer |
NCT02760030 |
Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery |
NCT05190770 |
A Study of Oleogel-S10 Gel for the Treatment of Radiation Dermatitis in People With Breast Cancer |
NCT03546686 |
Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer |
NCT05812924 |
A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause |
NCT03598257 |
Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer |
NCT04998682 |
Prospective Evaluation of Targeted Axillary Dissection (TAD) |
NCT04899908 |
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases |
NCT04348747 |
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer |
NCT04871516 |
Radiation Therapy Boost Before Surgery for the Treatment of Non-metastatic Breast Cancer |
NCT02912312 |
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer |
NCT03804944 |
Converting HR+ Breast Cancer Into an Individualized Vaccine |
NCT04683679 |
A Study of Radiation Therapy With Pembrolizumab and Olaparib or Other Radiosensitizers in Women Who Have Triple-Negative or Hormone-Receptor Positive/Her2 Negative Breast Cancer |
NCT04521764 |
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer |
NCT04120246 |
Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer |
NCT02290834 |
Chemotherapy-induced Cognitive and Brain Changes in Older Adults With Breast Cancer |
NCT06081127 |
Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function |
NCT06026657 |
Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer |
NCT02945579 |
Eliminating Surgery or Radiotherapy After Systemic Therapy in Treating Patients With HER2 Positive or Triple Negative Breast Cancer |
NCT04443348 |
Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD) |
NCT05142358 |
A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose |
NCT05226663 |
A Radiotracer ([18F]FluorThanatrace) by PET/CT for the Imaging of Breast Cancer |
NCT05890677 |
The LYMPH Trial - Surgical Versus Conservative Complex Physical Decongestion Therapy for Chronic Breast Cancer-Related Lymphedema |
NCT04616248 |
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors |
NCT06260332 |
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors |
NCT05534438 |
A Study on Adding Precisely Targeted Radiation Therapy (Stereotactic Body Radiation Therapy) to the Usual Treatment Approach (Drug Therapy) in People With Breast Cancer |
NCT05807074 |
Impact of Topical Tranexamic Acid in Breast Reconstruction |
NCT03941756 |
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer |
NCT04009044 |
Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast |
NCT04946864 |
A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer |
NCT05455658 |
STEMVAC in Patients With Early Stage Triple Negative Breast Cancer |
NCT05464082 |
Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC |
NCT04084730 |
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer |
NCT05505643 |
Cryoablation vs Lumpectomy in T1 Breast Cancers |
NCT05376878 |
An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastasis |
NCT05098210 |
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer |
NCT05809752 |
A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) |
NCT06133348 |
Promoting Resilience in Women With Breast Cancer |
NCT04568616 |
Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI) |
NCT03694756 |
TMEM-MRI: A Pilot Feasibility Study of MRI for Imaging of TMEM in Patients With Operable Breast Cancer |
NCT04266249 |
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy |
NCT03213041 |
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer |
NCT05554211 |
Tranexamic Acid Usage in Bilateral Mastectomy to Reduce Post-surgical Drainage |
NCT04389281 |
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma |
NCT04003038 |
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery |
NCT04534010 |
Decellularized, Whole Donor Nipple-Areola Complex Reconstruction Grafts |
NCT04049214 |
Perioperative Mindfulness Proposal |
NCT04553770 |
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer |
NCT05677802 |
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer |
NCT04364672 |
Molecular Neuroimaging to Assess the Link Between Neuroinflammation and Cognitive Impairment in Breast Cancer |
NCT04606030 |
LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge) |
NCT05633654 |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy |
NCT04636710 |
Refining Local-Regional Therapy for IBC |
NCT03808337 |
Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease |
NCT06086704 |
Study of 18F-FFNP Breast PET/MRI |
NCT06058650 |
Molecular Breast Imaging Guidance for Breast Biopsy for Patients With Breast Abnormalities |
NCT04445844 |
INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study |
NCT05756166 |
Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer |
NCT06219434 |
Evaluation of a Mindfulness Intervention to Prevent Chemo-brain in Women Preparing for Chemotherapy for Breast Cancer |
NCT05595499 |
Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors |
NCT05219695 |
Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI) |
NCT06315296 |
An Interactive Time-Restricted Diet Intervention (txt4fasting) for Reducing Neurocognitive Decline and Improving Survival in Patients With Brain Metastases From Breast or Lung Cancer |
NCT03572374 |
Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job |
NCT05074290 |
Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patients |
NCT03820141 |
Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer |
NCT05704283 |
3D Ultrasound for the Imaging of Axillary Lymph Nodes in Patients With Breast Cancer |
NCT05319873 |
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer |
NCT05023967 |
Metformin and Nightly Fasting in Women With Early Breast Cancer |
NCT05673200 |
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer |
NCT05795101 |
TRUDI: TDXD+Durva in HER2+/Low IBC |
NCT05585788 |
Opioid Dispensing Device for Post-Operative Pain in Cancer Patients Patients |
NCT03696030 |
HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases |
NCT05929768 |
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer |
NCT06220214 |
Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer |
NCT03742102 |
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer |
NCT04197687 |
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery |
NCT05557877 |
Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer |
NCT04824027 |
Breast Elasticity Imaging During Neoadjuvant Chemotherapy |
NCT05313191 |
Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors |
NCT05372640 |
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors |
NCT05768139 |
First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors |
NCT05846789 |
Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers |
NCT06165419 |
Definitive Radiation for High-Risk Spine Metastases |
NCT03801369 |
Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer |
NCT03796559 |
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes |
NCT03095352 |
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease |
NCT05113927 |
Wide Field OCT + AI for Positive Margin Rates in Breast Conservation Surgery. |
NCT04711824 |
Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases |
NCT03351348 |
Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control |
NCT04647916 |
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases |
NCT05954143 |
Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer |
NCT05076760 |
MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer |
NCT05190978 |
Randomized Feasibility Trial for Mesh in Pre-Pectoral Reconstruction |
NCT04072393 |
Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers |
NCT03321045 |
Positron Emission Tomography (PET) Imaging With Zirconium-89 (89Zr)-Trastuzumab for Prediction of HER2 Targeted Therapy Effectiveness |
NCT05837767 |
A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue |
NCT05291507 |
Feasibility Evaluation of the Muse Magnetic Resonance Guided Focused Ultrasound System |
NCT05744557 |
Vapocoolant Analgesia for Breast Lymphoscintigraphy |
NCT04768426 |
Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer |
NCT03272334 |
Her2-BATS and Pembrolizumab in Metastatic Breast Cancer |
NCT04677816 |
Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients |
NCT04796220 |
Focused Ultrasound and Gemcitabine in Breast Cancer |
NCT06072612 |
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. |
NCT05629585 |
A Study of Dato-DXd With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Without Pathological Complete Response Following Neoadjuvant Therapy (TROPION-Breast03) |
NCT05146297 |
Diversity and Inclusion in Research Underpinning Prevention and Therapy Trials |
NCT03960463 |
EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds |
NCT03504488 |
CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2) |
NCT05747794 |
Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy |
NCT04147494 |
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues |
NCT06058377 |
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer |
NCT04265872 |
Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC |
NCT05203445 |
A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer |
NCT03428802 |
Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability |
NCT05232916 |
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects |
NCT05144698 |
RAPA-201 Therapy of Solid Tumors |
NCT06112379 |
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer |
NCT06299163 |
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors |
NCT06103669 |
Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS) |
NCT04673448 |
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer |
NCT05949021 |
OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer |
NCT05950945 |
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer |
NCT05720039 |
Robotic vs. Open NSM for Early Stage Breast Cancer |
NCT05633979 |
Phase 1b Study of EZH1/2 Inhibitor Valemetostat in Combination With Trastuzumab Deruxtecan in Subjects With HER2 Low/Ultra-low/Null Metastatic Breast Cancer |
NCT04650256 |
Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences |
NCT04756765 |
Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer |
NCT06100874 |
A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After progrEssion on ENhertu (SATEEN) |
NCT05694364 |
Dose Escalation/Dose Expansion Study of PRGN-3007 UltraCAR-T Cells in Patients With Advanced Hematologic and Solid Tumor Malignancies |
NCT04891068 |
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer |
NCT03449238 |
Pembrolizumab And Stereotactic Radiosurgery (Srs) Of Selected Brain Metastases In Breast Cancer Patients |
NCT04090398 |
Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones |
NCT03562637 |
Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC |
NCT04478279 |
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors |
NCT05693766 |
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort |
NCT05269381 |
Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors |
NCT03075072 |
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial |
NCT05069038 |
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy |
NCT04588246 |
Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in People With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery |
NCT04549571 |
Improving Patient-Centered Communication in Breast Cancer Through Patient and Provider Interventions |
NCT04315233 |
Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By Genomics |
NCT03606967 |
Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer |
NCT05545150 |
Volumetric Specimen Imager Device for the Intraoperative Imaging of Patients With Breast Carcinoma and Breast Ductal Carcinoma In Situ, The VIVID Study |
NCT05453825 |
A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors |
NCT04144023 |
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ |
NCT06027268 |
Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer |
NCT03463954 |
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors |
NCT04187898 |
Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer |
NCT05163223 |
Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer |
NCT04986579 |
Scalp Cooling in MBC |
NCT06246968 |
A Study of Pembrolizumab and Cryoablation in People With Breast Cancer |
NCT05078398 |
Postoperative Opt-In Narcotics Treatment in Breast |
NCT04282044 |
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies |
NCT05568472 |
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study |
NCT05703269 |
Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy |
NCT04699630 |
A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer |
NCT04333706 |
A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) |
NCT05020574 |
Microbiome and Association With Implant Infections |
NCT03025035 |
Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer |
NCT05183126 |
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer |
NCT06144164 |
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer |
NCT04090567 |
Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer |
NCT03742245 |
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer |
NCT04243616 |
Cemiplimab in High Risk or Locally Advanced Hormone Receptor Positive HER2 Negative or Triple-Negative Breast Cancer |
NCT02778685 |
Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients With Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer |
NCT01174121 |
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer |
NCT04669301 |
Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II |
NCT05218044 |
Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ |
NCT06085742 |
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer |
NCT03740256 |
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors |
NCT06239467 |
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer |
NCT04704661 |
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial |
NCT05092373 |
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax |
NCT05826964 |
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer |
NCT05113251 |
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer |
NCT05553522 |
Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer |
NCT06245889 |
PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC |
NCT05675579 |
A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) |
NCT05746897 |
A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors |
NCT04965064 |
Trial of Neratinib Plus Capecitabine in Subjects With HER2-Negative Metastatic Breast Cancer With Brain Metastases and Abnormally Active HER2 Signaling |
NCT05305924 |
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer |
NCT04222413 |
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors |
NCT05812807 |
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab |
NCT05748834 |
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer |
NCT03971409 |
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer |
NCT04703920 |
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer |
NCT05180474 |
GEN1047 for Solid Tumors - First in Human (FIH) Trial |
NCT05933395 |
Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor |
NCT04457596 |
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial |
NCT04475640 |
Cancer Genetic Testing in Ethnic Populations |
NCT04644068 |
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies |
NCT02993159 |
Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast |
NCT05101564 |
Umbrella Trial Testing Integrative Subtype-Targeted Therapeutics in HR+ /HER2-Negative Breast Cancer |
NCT03589339 |
NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy |
NCT05524584 |
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer |
NCT05150652 |
Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer |
NCT02830724 |
Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers |
NCT06328738 |
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer |
NCT05095207 |
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer |
NCT04174352 |
FES Imaging to Optimize Tamoxifen for Metastatic Breast Cancer |
NCT06042569 |
Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial |
NCT05020860 |
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer |
NCT05256745 |
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer |
NCT05274451 |
A Study to Investigate LYL797 in Adults With Solid Tumors |
NCT04722692 |
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ |
NCT06145399 |
A Study of 1 8F-FDHT PET/MRIScans in Women With Breast Cancer |
NCT02476786 |
Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score |
NCT05111561 |
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer |
NCT03990896 |
Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial |
NCT03934905 |
Protective Effects of the Nutritional Supplement Sulforaphane on Doxorubicin-Associated Cardiac Dysfunction |
NCT05607004 |
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer |
NCT05585034 |
Phase 1, First-in-human, Dose-finding and Expansion Study to Evaluate XmAb®808 in Combination With Pembrolizumab in Advanced Solid Tumors |
NCT04205903 |
Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients With Stage I-III Breast Cancer |
NCT03671044 |
A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients |
NCT04787042 |
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 |
NCT05655598 |
TAS-116 Plus Palbociclib in Breast and Rb-null Cancer |
NCT03604315 |
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF |
NCT04039230 |
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer. |
NCT05608252 |
VS-6766+Abema+Fulv in Met HR+/HER- BC |
NCT04692831 |
Testing a New Imaging Agent to Identify Cancer |
NCT04494945 |
Identifying and Caring for Individuals With Inherited Cancer Syndrome |
NCT02276443 |
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative |
NCT04862585 |
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel |
NCT05554354 |
Testing the Use of Fulvestrant and Binimetinib Targeted Treatment for NF1 Mutation in Hormone Receptor-Positive Metastatic Breast Cancer (A ComboMATCH Treatment Trial) |
NCT04542135 |
Sulindac and Breast Density in Women at Risk of Developing Breast Cancer |
NCT06018337 |
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) |
NCT05458674 |
Tucatinib+Trastuzumab+Eribulin in HER2+ MBC |
NCT05501704 |
ETHAN - ET for Male BC |
NCT02095184 |
GCC 1366: Anti-Proliferative Response to NeoAdjuvant AIs in Overweight and Obese Patients |
NCT05230810 |
Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer. |
NCT04614194 |
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib |
NCT06052852 |
Study of BDC-3042 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Malignancies |
NCT02422641 |
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis |
NCT05251714 |
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer |
NCT04967976 |
Breast Mesh Used in Two-staged Breast Reconstruction |
NCT02694809 |
The PROMISE Study: Duavee in Women With DCIS |
NCT04762979 |
Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer |
NCT05576077 |
A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors |
NCT06253520 |
Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer |
NCT05700669 |
Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors |
NCT02872025 |
Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS) |
NCT02484404 |
Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can... |
NCT04119024 |
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma |
NCT04886531 |
Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers |
NCT04072952 |
A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer |
NCT05498155 |
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer |
NCT05894239 |
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer |
NCT05132582 |
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer |
NCT03975647 |
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer |
NCT03368729 |
Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer |
NCT04550494 |
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations |
NCT03832855 |
Assessing the Immunogenicity of pING-hHER3FL |
NCT05383196 |
Onvansertib + Paclitaxel In TNBC |
NCT05464810 |
Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer |
NCT04964934 |
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) |
NCT05259696 |
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01) |
NCT03412877 |
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer |
NCT05029999 |
CD40 Agonist, Flt3 Ligand, and Chemotherapy in Triple Negative Breast Cancer |
NCT04584255 |
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer |
NCT04589468 |
Researching the Effect of Exercise on Cancer |
NCT05877599 |
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation |
NCT06218303 |
Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ |
NCT01042379 |
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer |
NCT06103864 |
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer |
NCT05564377 |
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial |
NCT03090165 |
Ribociclib and Bicalutamide in AR+ TNBC |
NCT05374512 |
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) |
NCT03424005 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer |
NCT03412643 |
Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling |
NCT05207709 |
Ribociclib vs. Palbociclib in Patients With Advanced Breast Cancer Within the HER2-Enriched Intrinsic Subtype |
NCT05307705 |
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors |
NCT04230109 |
Sacituzumab Govitecan In TNBC |
NCT05852691 |
A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer |
NCT04849364 |
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer |
NCT05483491 |
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer |
NCT04873362 |
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy |
NCT05840211 |
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy |
NCT05296798 |
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) |
NCT06022029 |
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. |
NCT04893109 |
ATEMPT 2.0: Adjuvant T-DM1 vs TH |
NCT05382286 |
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer |
NCT04567420 |
DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer |
NCT05966584 |
A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer |
NCT04862663 |
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292) |
NCT05774951 |
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy |
NCT05501886 |
Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1) |
NCT05654623 |
A Study to Learn About a New Medicine Called ARV-471 (PF-07850327) in People Who Have Advanced Metastatic Breast Cancer. |
NCT05382299 |
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer |
NCT05952557 |
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) |
NCT05646862 |
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy |
NCT04906395 |
Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer |
NCT06110793 |
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer |
NCT05696626 |
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation |
NCT06001762 |
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer |
NCT04841148 |
Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer |
NCT06075953 |
DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment |
NCT05323955 |
Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients With aDvanced Human Epidermal Growth Factor Receptor 2+ brEast Cancer With the Addition of Tucatinib |
NCT05963984 |
A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants |
NCT02264678 |
Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents |
NCT06065748 |
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) |
NCT04802759 |
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer |
NCT06105632 |
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment |
NCT03746431 |
A Phase 1/2 Study of [225Ac]-FPI-1434 Injection |
NCT05514054 |
A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer |
NCT05306340 |
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer) |
NCT05239143 |
P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors |
NCT04569747 |
A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer |
NCT05467891 |
Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer |
NCT05864144 |
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors |
NCT02488967 |
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer |
NCT04425018 |
MARGetuximab Or Trastuzumab (MARGOT) |
NCT04468061 |
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC |
NCT06016738 |
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer |
NCT04150042 |
SHARON: A Clinical Trial for Metastatic Cancer With a BRCA or PALB2 Mutation Using Chemotherapy and Patients' Own Stem Cells |
NCT04975308 |
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer |
NCT05262400 |
A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors |
NCT05645380 |
Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC |
NCT05765851 |
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors |
NCT03367572 |
Netupitant/Palonosetron Hydrochloride and Dexamethasone With or Without Prochlorperazine or Olanzapine in Improving Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer |
NCT05909397 |
A Study of ARV-471 (PF-07850327) Plus Palbociclib Versus Letrozole Plus Palbociclib in Participants With Estrogen Receptor Positive, Human Epidermal Growth Factor Negative Advanced Breast Cancer |
NCT05216432 |
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Advanced Solid Tumor Patients and in Combination With Fulvestrant in Patients With Advanced Breast Cancer |
NCT05563220 |
Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer |
NCT06120283 |
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors |
NCT05417594 |
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies |
NCT05161195 |
Roll-over Study to Allow Continued Access to Ribociclib |
NCT05082610 |
A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab |
NCT03930680 |
Prevention of Heart Failure Induced by Doxorubicin With Early Administration of Dexrazoxane |
NCT06188520 |
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors |
NCT05751668 |
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) |
NCT04180371 |
Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression |
NCT05035407 |
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers |
NCT04925284 |
Study of XB002 in Subjects With Solid Tumors (JEWEL-101) |
NCT05000294 |
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types |
NCT03011684 |
Fertility Preservation Using Tamoxifen and Letrozole in Estrogen Sensitive Tumors Trial |
NCT05868226 |
PRE-I-SPY Phase I/Ib Oncology Platform Program |
NCT05277051 |
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors |
NCT04042701 |
DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer |
NCT05007106 |
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) |
NCT05593094 |
A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors |
NCT02632448 |
A Study of LY2880070 in Participants With Advanced or Metastatic Cancer |
NCT04319757 |
ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors |
NCT04771520 |
Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors |
NCT04278144 |
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors |
NCT05150691 |
A Study of DB-1303 in Advanced/Metastatic Solid Tumors |
NCT04561362 |
Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies |
NCT05252390 |
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors |
NCT05226871 |
Study for Participants Continuing From Pfizer-sponsored Palbociclib (a Study Medicine) Studies |
NCT06065059 |
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors |
NCT06257264 |
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors |
NCT06157892 |
A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors |
NCT05208762 |
A Study of SGN-PDL1V in Advanced Solid Tumors |
NCT04553133 |
PF-07104091 as a Single Agent and in Combination Therapy |
NCT04570956 |
Oral Tamoxifen vs. TamGel vs. Control in Women With Atypical Hyperplasia or Lobular Carcinoma In Situ |
NCT05544929 |
A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers |
NCT04143711 |
Study of DF1001 in Patients With Advanced Solid Tumors |
NCT04389632 |
A Study of SGN-B6A in Advanced Solid Tumors |
NCT04606446 |
Study of PF-07248144 in Advanced or Metastatic Solid Tumors |
NCT05708950 |
A Clinical Trial of KVA12123 Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) |
NCT05252416 |
(VELA) Study of BLU-222 in Advanced Solid Tumors |
NCT05650879 |
ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer |
NCT05215574 |
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors |
NCT05070247 |
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors |
NCT05887492 |
Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors |
NCT04913337 |
Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies |
NCT04585750 |
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) |
NCT04140526 |
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC |
NCT04557449 |
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors |
NCT05107674 |
A Study of NX-1607 in Adults With Advanced Malignancies |
NCT03568656 |
Study to Evaluate CCS1477 in Advanced Tumours |
NCT05891171 |
Study of AB598 Monotherapy and Combination Therapy in Participants With Advanced Cancers |
NCT05086692 |
A Beta-only IL-2 ImmunoTherapY Study |
NCT06270706 |
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors |
NCT04895709 |
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors |
NCT05827614 |
Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), in Subjects With Tumors With Oncogene Amplifications |
NCT05325866 |
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression |
NCT05898399 |
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients |
NCT04225117 |
A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) |
NCT04373564 |
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years |
NCT05888831 |
A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors |
NCT05500508 |
Oral AMXT 1501 Dicaprate in Combination With IV DFMO |
NCT05537740 |
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors |
NCT04300556 |
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types |